Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma

• Published in: Aging (Albany, NY.) Vol. 16; no. 11; pp. 9899 - 9917
• Main Authors: Dong, Xiaoqi, Shao, Chuan, Xu, Shuguang, Tu, Jinjing, Xu, Wenjing, Chen, Dahua, Tang, Yaodong
• Format: Journal Article
• Language: English
• Published: United States Impact Journals 07.06.2024
• Subjects: Research Paper; lncRNAs; anoikis; signature; prognosis; lung adenocarcinoma
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.205905

Lung adenocarcinoma (LUAD) is the most common type of lung cancer and is characterized by a high death rate and a poor prospect for survival. Anoikis, which is a kind of programmed cell apoptosis, is an important factor in the advancement of tumors. Nonetheless, the function of anoikis-related lncRNAs (ARLRs) in LUAD is still not well understood. The TCGA database was queried for genomic and clinical information. A prognostic signature for ARLRs was established via the use of coexpression analysis and Cox regression. Validation of the model's accuracy was conducted utilizing K-M curves and receiver operating characteristic (ROC) curves, and the signature was utilized to develop a nomogram. LncRNAs were implicated in the progression of tumors, as determined by functional enrichment analysis. There was an improvement in prognosis, increased immune cell infiltration, and higher immune scores among the low-risk patients. Additionally, we found that the two groups had varied anticancer drug sensitivities, which could help guide treatment. The impact of one ARLR, AC026355.2, on migration and invasion was validated by experiments in LUAD cells. Herein, a new lncRNA signature associated with anoikis was identified and estimated, potentially serving as a prognostic indicator for LUAD patients.